Canine Congestive Heart Failure Study Guide

NAVLE Examination Preparation

Cardiovascular System | Species: Canine

Estimated Read Time: 35-45 minutes | Last Updated: December 2024

Overview and Clinical Importance

Congestive heart failure (CHF) is a clinical syndrome that occurs when the heart can no longer pump sufficient blood to meet the body's metabolic demands, or can only do so at elevated filling pressures. In dogs, CHF most commonly results from myxomatous mitral valve disease (MMVD), accounting for approximately 75% of all canine heart disease cases. The second most common cause is dilated cardiomyopathy (DCM), which predominantly affects large and giant breed dogs. Understanding the pathophysiology, clinical presentation, diagnostic approach, and treatment of CHF is essential for NAVLE success and clinical practice.

Heart failure in dogs carries significant morbidity and mortality. Approximately 10% of dogs presented to primary care veterinary practices have heart disease, making cardiovascular conditions a major component of the NAVLE examination. Early recognition and appropriate staging of heart disease directly impacts treatment decisions and patient outcomes.

Learning Objectives

• Classify congestive heart failure using the ACVIM staging system (Stages A through D)
• Differentiate between left-sided and right-sided heart failure based on clinical signs
• Identify breed predispositions for MMVD and DCM
• Interpret radiographic and echocardiographic findings consistent with CHF
• Select appropriate pharmacologic therapy for acute and chronic CHF management
• Understand the clinical significance of the EPIC trial for preclinical disease management

Pathophysiology of Congestive Heart Failure

Hemodynamic Basis

Heart failure develops when cardiac output becomes insufficient to meet tissue oxygen demands. The failing heart triggers compensatory mechanisms including:

• Renin-Angiotensin-Aldosterone System (RAAS) activation: Causes sodium and water retention, vasoconstriction, and cardiac remodeling
• Sympathetic nervous system activation: Increases heart rate and contractility but also increases myocardial oxygen demand
• Cardiac remodeling: Chamber dilation and hypertrophy that initially maintains output but eventually becomes maladaptive
• Natriuretic peptide release: Counterregulatory mechanism attempting to promote natriuresis and vasodilation

High-Yield Note: When left atrial pressure exceeds 25 mmHg, pulmonary edema develops. This is the hallmark of left-sided CHF and explains why dogs present with coughing and respiratory distress.

Left-Sided vs. Right-Sided Heart Failure

Understanding the anatomic basis of CHF helps predict clinical signs and guides diagnostic interpretation.

Board Tip: Left-sided CHF is far more common in dogs than right-sided CHF. When you see a small breed dog with a heart murmur, cough, and tachypnea, think MMVD with left-sided CHF first. When you see ascites and jugular distension, think right-sided or biventricular failure.

Figure 1 - Lateral thoracic radiograph of a dog with left-sided CHF showing cardiomegaly with left atrial enlargement, dorsal elevation of the trachea, and perihilar pulmonary edema pattern. (A). cardiogenic pulmonary edema due to severe mitral regurgitation and (B) body of the left atrium almost touching the spine. Courtesy of Dr. Mark D. Kittleson. Accessed from https://www.merckvetmanual.com/multimedia/image/congestive-heart-failure-dog-radiograph

ACVIM Staging System for Heart Disease

The American College of Veterinary Internal Medicine (ACVIM) consensus guidelines provide a standardized staging system that guides treatment decisions. This staging system is adapted from human medicine and is essential knowledge for the NAVLE.

High-Yield Note: The EPIC study (2016) revolutionized treatment of preclinical heart disease. Dogs with Stage B2 MMVD treated with pimobendan had a median 15-month delay in onset of CHF compared to placebo. This is why pimobendan is now indicated for Stage B2 disease, not just Stage C.

Common Causes of Canine CHF

Myxomatous Mitral Valve Disease (MMVD)

MMVD is the most common acquired heart disease in dogs, accounting for approximately 75% of canine cardiovascular disease. It is characterized by progressive myxomatous degeneration of the mitral valve leaflets, causing mitral regurgitation.

Breed Predispositions

• Cavalier King Charles Spaniel: Highest prevalence, often develops at younger age (may have murmur by 1-2 years)
• Other small breeds: Miniature Poodle, Chihuahua, Miniature Schnauzer, Cocker Spaniel, Dachshund, Yorkshire Terrier
• Age: Prevalence increases with age; up to 85% of small breed dogs show evidence by 13 years
• Sex: Males affected 1.5 times more commonly than females

Clinical Findings

• Murmur: Left apical systolic murmur, grade increases with disease severity
• Radiography: Left atrial enlargement (dorsal deviation of trachea, splaying of mainstem bronchi), left ventricular enlargement, pulmonary venous distension
• Echocardiography: Thickened, prolapsing mitral valve leaflets; mitral regurgitation on color Doppler; LA/Ao ratio greater than or equal to 1.6 indicates significant enlargement

Figure 2 - Echocardiogram showing mitral valve regurgitation with color Doppler flow and left atrial enlargement in a dog with MMVD. Image credit: https://todaysveterinarypractice.com/cardiology/congestive-heart-failure-in-dogs/

Dilated Cardiomyopathy (DCM)

DCM is characterized by progressive loss of myocardial contractility with ventricular dilation and wall thinning. It predominantly affects large and giant breed dogs and carries a more guarded prognosis than MMVD.

Breed Predispositions

Memory Tip - Doberman DCM: "Double Doom"

• Double screening: Echo AND Holter annually starting at age 3
• Double trouble: VPCs greater than 300/24hr OR 50-300 on two consecutive readings = diagnostic
• Double-digit survival: Only 3-6 months median survival after CHF develops

Diagnostic Approach

Physical Examination

• Auscultation: Murmur grade and location, arrhythmias, gallop sounds, pulmonary crackles
• Respiratory assessment: Rate, effort, orthopnea, cyanosis
• Pulse quality: Weak pulses suggest low output; pulse deficits indicate arrhythmia
• Jugular assessment: Distension or pulsations indicate right-sided failure

Thoracic Radiography

Radiography is the primary diagnostic tool for confirming CHF and is essential for staging.

Radiographic Signs of Left-Sided CHF

• Cardiomegaly: Increased VHS, loss of waist, increased sternal contact
• Left atrial enlargement: Dorsal elevation of trachea and carina, splaying of mainstem bronchi
• Pulmonary venous distension: Veins larger than accompanying arteries
• Pulmonary edema: Perihilar to caudodorsal distribution, interstitial to alveolar pattern

Figure 3 – VHS (moderate cardiomegaly in a dog with a VHS of 11.5) measurement technique on lateral thoracic radiograph demonstrating how to measure the long and short axis of the heart and compare to vertebral bodies starting at T4.

Reference and image credit: https://vetmed.illinois.edu/2022/07/06/evaluating-the-heart-size-on-radiographs/

Echocardiography

Echocardiography is the gold standard for diagnosing underlying cardiac disease and assessing severity.

Board Tip: In MMVD, fractional shortening is often ELEVATED (greater than 45%) due to volume overload, not decreased. A low or low-normal FS in advanced MMVD is a poor prognostic sign suggesting myocardial failure is developing.

Treatment of Congestive Heart Failure

Emergency Management of Acute CHF

Dogs presenting in acute respiratory distress require immediate stabilization. Minimize stress - even handling for diagnostics can be fatal in severely compromised patients.

Initial Stabilization Protocol

• Oxygen supplementation: Flow-by, oxygen cage, or nasal cannula
• Furosemide IV bolus: 2-4 mg/kg IV or IM; repeat every 30-60 minutes until respiratory rate decreases
• Furosemide CRI (alternative): 0.66-1 mg/kg/hour IV
• Pimobendan: 0.25-0.3 mg/kg PO; onset of action within 1 hour
• Sedation if needed: Butorphanol 0.2-0.4 mg/kg IV or IM for anxiety/dyspnea

High-Yield Note: NEVER give IV fluids to a patient in acute CHF - they already have volume overload! Allow free access to water once diuresis begins, but IV fluid administration is contraindicated.

Chronic Management - Drug Therapy

Memory Tip - CHF Drug Therapy: "FAPS"

• F = Furosemide (loop diuretic)
• A = ACE inhibitor (enalapril/benazepril)
• P = Pimobendan (inodilator)
• S = Spironolactone (aldosterone antagonist)

Refractory Heart Failure (Stage D)

When standard therapy fails, escalation strategies include:

• Increase furosemide frequency: q8h or even q6h dosing
• Switch to torsemide: More potent loop diuretic with better bioavailability; dose at approximately 10% of furosemide dose
• Add hydrochlorothiazide: 0.5-1 mg/kg PO q24h for sequential nephron blockade
• Sildenafil: 1-2 mg/kg PO q8-12h for pulmonary hypertension
• Increase pimobendan: Off-label doses up to 0.4 mg/kg TID have been used safely

Prognosis and Survival

High-Yield Note: Cardiac cachexia (unintended weight loss with muscle wasting) is a poor prognostic indicator. Dogs losing weight despite adequate caloric intake have activation of catabolic pathways and advanced disease.

Landmark Clinical Trials

EPIC Study (2016)

• Population: 360 dogs with Stage B2 MMVD
• Intervention: Pimobendan vs. placebo
• Result: Median 15-month delay in onset of CHF with pimobendan
• Clinical significance: Changed standard of care - pimobendan now indicated for Stage B2

QUEST Study

• Finding: Pimobendan superior to benazepril alone for Stage C MMVD

BESST Trial

• Finding: Adding spironolactone to ACE inhibitor improves outcomes

PROTECT Study

• Finding: Pimobendan delays CHF onset by approximately 9 months in preclinical Doberman DCM

Practice Question

Correct Answer: B

Explanation

Furosemide, pimobendan, and enalapril (Option B) is correct because this patient is in Stage C congestive heart failure. The clinical evidence for CHF includes: nocturnal cough, exercise intolerance, tachypnea at rest (48 bpm is elevated), pulmonary crackles on auscultation, radiographic evidence of cardiomegaly (VHS 12.5 is markedly elevated), and pulmonary edema (perihilar interstitial-alveolar pattern). This patient requires "triple therapy" with a diuretic (furosemide) to remove pulmonary edema, an inodilator (pimobendan) for positive inotropy and afterload reduction, and an ACE inhibitor (enalapril) for neurohormonal modulation and afterload reduction.

Option A (Enalapril alone) is incorrect because ACE inhibitors alone are insufficient for treating active CHF. This patient has pulmonary edema and requires diuretic therapy. ACE inhibitors are important but do not directly remove fluid.

Option C (Pimobendan alone) is incorrect because this patient is NOT in Stage B2 - they have progressed to Stage C with active CHF. While pimobendan monotherapy is appropriate for Stage B2 (based on the EPIC study), patients with clinical signs of CHF require diuretics and typically ACE inhibitors as well.

Option D (Atenolol) is incorrect and potentially dangerous. Beta-blockers have negative inotropic effects and should never be administered to patients with acute CHF. The patient's heart rate of 140 bpm is a compensatory response and the tachycardia is appropriate - suppressing it would decrease cardiac output.

Option E (Digoxin) is incorrect because digoxin is no longer a first-line agent for CHF. Pimobendan has largely replaced digoxin due to superior efficacy and safety profile. Digoxin may be considered for rate control in atrial fibrillation but is not indicated as primary therapy here.

Board Tip: When you see a CKCS with a murmur, nocturnal cough, and radiographic evidence of cardiomegaly with pulmonary infiltrates, think MMVD with left-sided CHF (Stage C). The treatment is "triple therapy" - Furosemide + Pimobendan + ACE inhibitor. Remember that CKCS are highly predisposed to MMVD and can develop disease at a younger age than other breeds.

Summary - Key Takeaways

• CHF occurs when the heart cannot maintain adequate output; most common causes are MMVD (75%) and DCM
• Left-sided CHF causes pulmonary edema (cough, dyspnea); right-sided CHF causes ascites and peripheral edema
• ACVIM staging guides treatment: Stage B2 = pimobendan; Stage C = triple therapy (furosemide + pimobendan + ACE inhibitor)
• EPIC study: Pimobendan delays CHF onset by 15 months in Stage B2 MMVD
• VHS greater than 10.5 suggests cardiomegaly; VHS greater than or equal to 11.5 with LA/Ao greater than or equal to 1.6 defines Stage B2
• Acute CHF: Oxygen, IV furosemide (2-4 mg/kg), pimobendan; NEVER give IV fluids
• Prognosis: MMVD Stage C median survival 6-14 months; Doberman DCM has poorest prognosis (3-6 months)
• Beta-blockers are contraindicated in acute CHF due to negative inotropic effects

Image Sources

• Figure 1: Lateral thoracic radiograph - Congestive heart failure with pulmonary edema. Source: Merck Veterinary Manual - Multimedia. Available at: https://www.merckvetmanual.com/multimedia/image/congestive-heart-failure-dog-radiograph (Free educational use)
• Figure 2: Color Doppler echocardiogram showing mitral regurgitation. Source: Today's Veterinary Practice - "Congestive Heart Failure in Dogs: Treatment and Management" - Figure 4. Available at: https://todaysveterinarypractice.com/cardiology/congestive-heart-failure-in-dogs/ (Open access educational content)
• Figure 3: VHS measurement technique. Source: University of Illinois College of Veterinary Medicine - "Evaluating the Heart Size on Radiographs" - Figure 1. Available at: https://vetmed.illinois.edu/2022/07/06/evaluating-the-heart-size-on-radiographs/ (Educational institution - free access)

References

• Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33:1127-1140.
• Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC study—a randomized clinical trial. J Vet Intern Med. 2016;30:1765-1779.
• Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23:1142-1150.
• Häggström J, Boswood A, O'Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving pimobendan or placebo: The EPIC study. J Vet Intern Med. 2017;31:1569-1582.
• O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med. 2008;22:897-904.
• Bernay F, Bland JM, Häggström J, et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med. 2010;24:331-341.
• Merck Veterinary Manual. Congestive Heart Failure in Dogs and Cats. Available at: https://www.merckvetmanual.com
• Cornell University College of Veterinary Medicine. Canine Dilated Cardiomyopathy (DCM). Available at: https://www.vet.cornell.edu/hospitals/services/cardiology/canine-dilated-cardiomyopathy-dcm